The global in situ hybridization market size was estimated at USD 1.60 billion in 2023 and is projected to reach USD 2.55 billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030. The market’s expansion is primarily driven by the growing demand for molecular diagnostic tools, with ISH technology gaining increasing adoption due to its precision in detecting genetic and cellular abnormalities.

The rising prevalence of cancer, coupled with the approval of multiple targeted therapies and continuous advancements in ISH technology, is a major factor fueling market growth. The increasing number of cancer cases has prompted governments, particularly in developing countries, to adopt technologically advanced diagnostic methods such as ISH for early detection and improved patient outcomes. In response to the high incidence of cancer, public authorities are also investing in and supporting the development of advanced diagnostic solutions.

The growing incidence of cancer is closely linked to lifestyle factors such as smoking and unhealthy dietary habits, which serve as significant drivers of the market. According to the National Cancer Institute (NCI), the U.S. reported approximately 1,898,160 new cancer cases and 608,570 cancer-related deaths in 2021. Globally, the World Health Organization (WHO) reported that by September 2021, 70% of cancer-related deaths occurred in low- and middle-income countries. In 2020, cancer was the leading cause of death worldwide, accounting for roughly 100 million deaths. Among all cancer types, breast cancer remained the most prevalent, with 2.26 million new cases and 685,000 deaths reported in 2020.

Key Market Trends & Insights:

• In 2023, North America dominated the global in situ hybridization (ISH) market, capturing the largest share of 44.04%. The region’s leadership is attributed to its well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and substantial investments in molecular diagnostics and cancer research. Strong government support, widespread awareness about early disease detection, and the presence of leading ISH technology providers further contribute to North America’s market dominance.

• In contrast, the Asia Pacific region is expected to experience the fastest growth during the forecast period. This rapid expansion is driven by increasing healthcare investments, rising awareness of molecular diagnostic tools, and the growing prevalence of cancer and other genetic disorders in developing economies. Expanding healthcare infrastructure and favorable government initiatives in countries such as China, India, and Japan are likely to fuel the adoption of ISH technologies in the region.

• When analyzed by end-use, the hospital and diagnostic laboratories segment held the largest revenue share of 49.4% in 2023. The dominance of this segment can be attributed to the increasing reliance on hospitals and diagnostic centers for early cancer detection, personalized treatment planning, and advanced molecular diagnostics. Hospitals and laboratories are equipped with state-of-the-art technologies and skilled professionals, making them key contributors to market growth.

• By technology, the FISH (fluorescence in situ hybridization) segment accounted for the largest market share of 53.84% in 2023. FISH technology is widely used due to its high specificity, sensitivity, and ability to detect genetic abnormalities at the cellular level, making it a preferred choice in clinical diagnostics and research applications.

• Regarding probe type, the DNA segment held the largest share of 57.0% in 2023. DNA probes are extensively used in ISH applications because of their ability to accurately target and detect specific genetic sequences, providing critical information for disease diagnosis, prognosis, and personalized treatment strategies.

Order a free sample PDF of the In Situ Hybridization Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 1.60 Billion

• 2030 Projected Market Size: USD 2.55 Billion

• CAGR (2024-2030): 7.2%

• North America: Largest market in 2023

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key players in the in situ hybridization (ISH) market are actively implementing a variety of strategic initiatives to maintain and strengthen their market positions, which is intensifying competition across the industry. These strategies encompass mergers and acquisitions, distribution agreements, new product development initiatives, and geographic expansion. By adopting such approaches, prominent market participants are not only enhancing their competitive edge but also addressing rising operational costs, thereby creating opportunities for increased profitability and sustainable growth.

For instance, in February 2023, Molecular Instruments, a spin-off of the California Institute of Technology, launched its HCR RNA-CISH kits. These kits are designed to enhance automated chromogenic ISH workflows that utilize RNAscope technology. The introduction of these kits allows laboratories to achieve double the turnaround time while reducing costs by half, offering a significant advantage in efficiency and affordability for RNA-based diagnostic testing.

In another development, in January 2023, Ikonisys SA entered into a strategic partnership with the Integrated Gulf Biosystems Group (IGB) to distribute the Ikoniscope20 Digital Fluorescence Microscope Solution across the Middle East, including countries such as Saudi Arabia, the UAE, Kuwait, and Bahrain, as well as South Asian markets. This collaboration is aimed at expanding the reach of Ikonisys’ oncology testing solutions, enabling broader adoption of advanced ISH technologies for cancer diagnostics in these emerging regions.

Key Players

• Thermo Fisher Scientific, Inc.

• Abbott

• PerkinElmer, Inc.

• BioView

• Agilent Technologies, Inc.

• Merck KGaA

• Bio-Rad Laboratories, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global in situ hybridization (ISH) market is experiencing significant growth, driven by the increasing demand for molecular diagnostic tools. Advancements in ISH technology, along with the rising prevalence of cancer and the approval of targeted therapies, are contributing to this expansion. Governments, particularly in developing countries, are adopting advanced diagnostic procedures like ISH for early cancer detection, leading to increased investments in healthcare infrastructure. The market is also witnessing technological innovations, such as the development of automated chromogenic ISH kits, which enhance workflow efficiency and reduce costs.